免疫治疗时代下膀胱癌保膀胱治疗的研究进展
Advances in bladder-preserving therapy for bladder cancer in the era of immunotherapy
刘天遥 1孙影 1杨荣 1郭宏骞1
作者信息
- 1. 南京大学医学院附属鼓楼医院泌尿外科(南京,210008)
- 折叠
摘要
膀胱癌是全球高发的恶性肿瘤之一,其中肌层浸润性膀胱癌(muscle invasive bladder cancer,MI-BC)患者的预后较差.新辅助治疗后的根治性膀胱切除加盆腔淋巴结清扫术是MIBC的标准治疗方案.然而,根治术造成的身体创伤和围术期并发症使患者的生活质量严重受损.各种保膀胱治疗策略逐渐成为无法耐受手术或拒绝手术患者的有效替代方案.免疫治疗具有疗效持久和高耐受性的优点,极大地改变了膀胱癌的治疗现状.免疫治疗的应用可能会显著提升保膀胱治疗的成功率.本文就常规保膀胱治疗方案和基于免疫治疗联合保膀胱治疗策略相关进展进行综述.
Abstract
Bladder cancer is one of the common malignant tumors worldwide,among which patients with muscle invasive bladder cancer(MIBC)have a poor prognosis.Radical cystectomy with pelvic lymph node dissec-tion after neoadjuvant therapy is the standard treatment for MIBC.However,the physical trauma and periopera-tive complications caused by radical surgery have seriously impaired the quality of life of patients.Various bladder-preserving treatment strategies have emerged as effective alternatives for patients who cannot tolerate surgery or refuse surgery.Immunotherapy,with the advantages of long-lasting efficacy and high tolerability,has dramatical-ly changed the treatment of bladder cancer.The application of immunotherapy may significantly improve the suc-cess rate of bladder-preserving treatment.This paper reviews the progress in conventional bladder-preserving treatment and immunotherapy-based combined bladder-preserving treatment strategies.
关键词
膀胱癌/肌层浸润性膀胱癌/保膀胱治疗/免疫治疗/标志物Key words
bladder cancer/muscle invasive bladder cancer/bladder-preserving treatment/immunotherapy/biomarker引用本文复制引用
出版年
2024
NETL
NSTL
万方数据